BioCentury
ARTICLE | Financial News

TherapeuticsMD raises $40 million in follow-on

July 31, 2014 1:32 AM UTC

Women's healthcare company TherapeuticsMD Inc. (NYSE:TXMD) raised $40 million through the sale of 8.6 million shares at $4.67 in a follow-on underwritten by Goldman Sachs and Noble Capital Markets. TherapeuticsMD proposed the follow-on late Tuesday, when its share price was $4.55.

TherapeuticsMD is developing a pipeline of hormone therapy products for menopause-related hormone deficiencies, with two products in Phase III testing: TX 12-001HR, an oral combination of estradiol and progesterone; and TX 12-002HR, an oral progesterone. The company also markets branded and generic prescription prenatal vitamins, as well as OTC vitamins and cosmetics. ...